How we started, and where we're going.

We wanted to know how Alzheimer's works.
Now we want to prevent it.

2019-2022

OneCarbon's Alzheimer's research begins

Yizhou Yu, OneCarbon's founder, begins his investigation into Alzheimer's Disease during his PhD at the University of Cambridge. It is here we discover the novel connection between Alzheimer's and one-carbon metabolism.

2023

Research wins global awards.

Yizhou uses machine learning to discover that a probiotic bacteria can be used to support one-carbon metabolism and receieves global recognition.

Winner of CSAR's student award, and 2nd out of 100 at global Falling Walls Lab finale.

Dr. Yizhou Yu at the Cambridge Society for the Application of Research awards
Yizhou at Falling Walls

2024

1C-01 evolved, manufactured, and tested (& more awards!)

We evolve 1C-01 for over a year, resulting in a bacteria with a specific mechanism - releasing one-carbon metabolites. We win the Trinity Bradfield prize and do first-in-human testing. OneCarbon is established to turn this research into an accessible product for neuronal resilience.

1C-01 manufactured and tested by team
Trinity Bradfield awards ceremony

2025

Pilot testing and Alzheimer's Society Innovation Launchpad

We do our first MVP launch with our local pilot group. OneCarbon is selected to join Alzheimer's Society's Innovation Launchpad programme.

Laura & (poorly-moustached) Jake with our first biomarker kit prototype
OneCarbon at the Alzheimer's Society's Launchpad event

Today

Large-scale biological validation & clinical trials.

We are looking for early adopters to provide feedback on 1C-01 and learn more about their microbiome. At the same time, we are beginning our clinical validation process.

The people behind the work

Dr Yizhou Yu

Dr Yizhou Yu

Co-Founder

Award-winning neuroscientist and computational biologist, with over 15 well-cited scientific publications. Over 8 years of experience leveraging computational biology, biochemistry, cell biology, and model organisms to investigate neurodegeneration and ageing.

Laura Galbraith

Laura Galbraith

Co-Founder

First class Oxford graduate (Human Sciences). Previous experience in biotech start-ups (iPSCs, and medical interventions in beauty & wellness), as well as financial services (Investment Banking). Motivated by family history of Alzheimer's Disease.

Suleyman Noordeen

Suleyman Noordeen

Medical Lead

Student doctor with multiple years of experience contributing to clinical research. Repeatedly recognised for his ability to communicate complex science to a breadth of internal and external community members.

Jake McMillan

Jake McMillan

Co-Founder

First class Oxford graduate (PPE). Previously founded a project management company supporting government contract operations. Financial and operational experience from financial sector roles.

Advisors

Dr Simon Galbraith

Dr Simon Galbraith

Chair

Previously the CEO and co-founder of Redgate Software for 20+ years. Chair at RoboK. Founder and Chief Executive of Cade Hill; Board member of numerous companies in the software and biotech sector.